Why products Nephron Pharmaceuticals Corporation?
Products Nephron Pharmaceuticals Corporation is a leading manufacturer of generic respiratory and 503B outsourcing medications. We produce affordable, high-quality inhalation solutions and suspension products that treat respiratory conditions, and we are the only manufacturer of Racemic Epinephrine, 2.25%, 0.5mL.
What kind of drugs does nephron make?
Nephron Pharmaceuticals Corporation manufactures generic respiratory medication products. The Company offers racepinephrine, albuterol sulfate, ipratropium bromide, and sodium chloride products. Nephron Pharmaceuticals serves customers worldwide.
How is nephron responding to the US drug shortage?
In an effort to alleviate the ongoing drug shortages in the US drug supply chain, Nephron has responded with 24-7 production of shortage products packaged in prefilled syringes and sterile small-volume parenteral solutions (SVPs).
Who is the Chief Commercial Officer at nephros?
Lobo first joined Nephros in February 2021 as Chief Marketing Officer. In the expanded role of Chief Commercial Officer, he will be responsible for all commercial strategy
Who owns Nephron Pharmaceuticals?
Lou KennedyLou Kennedy is President, CEO and Owner of Nephron Pharmaceuticals Corporation – a certified woman-owned business. She has held a variety of marketing and operational roles at Nephron and created the Nephron national sales force.
What is Nephron Pharmaceuticals Corporation?
Nephron Pharmaceuticals Corporation is a leading manufacturer of generic respiratory and 503B outsourcing medications. We produce affordable, high-quality inhalation solutions and suspension products that treat respiratory conditions, and we are the only manufacturer of Racemic Epinephrine, 2.25%, 0.5mL.
What does Nephron make?
Headquartered at 4500 12th Street in West Columbia, Nephron develops and produces safe, affordable respiratory health solutions and other medical products. Nephron is a global leader in the production of generic respiratory medications and blow-fill-seal contract manufacturing.
How many employees Nephron Pharmaceuticals?
Nephron Pharmaceuticals corporate office is located in 4500 12th Street Extension, West Columbia, South Carolina, 29172, United States and has 846 employees.
When was nephron founded?
1937It was founded in 1937 and headquartered in Florida, New York.
Where is the nephron located?
the kidneyThe nephron is the structural and functional unit of the kidney. There are about two million nephrons in each kidney. Nephrons begin in the cortex; the tubules dip down to the medulla, then return to the cortex before draining into the collecting duct.
What is the likely benefit of nephron?
The primary function of nephron is removing all waste products including the solid wastes, and other excess water from the blood, converting blood into the urine, reabsorption, secretion, and excretion of numerous substances.
Why are nephrons called dialysis bags?
Glomerulus are considered as dialysis bags because in nephron glomerulus filters the blood by not absorbing unwanted salts and urea back ,also by dialysis machine filteration of blood is done but artificialy. Therefore,we can say that glomerulus is considered as dialysis bag.
How many types of nephron are there?
There are two basic kinds of nephrons: cortical nephrons and juxtamedullary nephrons. These distinctions have to do with the location of the glomerulus, the tiny ball of capillary network, and the penetration into the medulla by the loops of the nephron tubule.
Is Nephron Pharmaceuticals a good place to work?
Nephron is a great place to launch your career, but I would not stay long-term. Lack of communication is rampant within the company and management poses an issue all the way up the chain. The pay is great, so if you can tolerate the sometimes chaotic environment, you will make out well.
What are the main functions of nephron?
The primary function of nephron is removing all waste products including the solid wastes, and other excess water from the blood, converting blood into the urine, reabsorption, secretion, and excretion of numerous substances.
What is nephron Pharm Corp sterile?
The Nephron 503B Outsourcing Facility is a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in the United States.
What is a nephron simple?
nephron, functional unit of the kidney, the structure that actually produces urine in the process of removing waste and excess substances from the blood. There are about 1,000,000 nephrons in each human kidney.
How many parts do nephrons have?
A nephron consists of six parts, i.e., Glomerulus, Bowman's capsule, Proximal convoluted tube, Loop of Henle, Distal convoluted tube, and the collecting duct. The glomerulus is made up of numerous capillaries enclosed in a glomerular capsule located in the cortex of the kidney.
Is NWPHF stock a buy right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Newron Pharmaceuticals in the last year. There are currently 1 hold rating...
How has Newron Pharmaceuticals' stock performed in 2022?
Newron Pharmaceuticals' stock was trading at $2.10 at the beginning of 2022. Since then, NWPHF shares have increased by 0.0% and is now trading at...
Who are Newron Pharmaceuticals' key executives?
Newron Pharmaceuticals' management team includes the following people: Mr. Stefan Weber , CEO & Exec. Director (Age 57, Pay $444.37k) Mr. Robert...
Who are some of Newron Pharmaceuticals' key competitors?
Some companies that are related to Newron Pharmaceuticals include Abliva AB (publ) (NEVPF) , Acusphere (ACUS) , ADC Therapeutics (ADCT) , Addex...
What is Newron Pharmaceuticals' stock symbol?
Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF."
How do I buy shares of Newron Pharmaceuticals?
Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Newron Pharmaceuticals' stock price today?
One share of NWPHF stock can currently be purchased for approximately $2.10.
How many employees does Newron Pharmaceuticals have?
Newron Pharmaceuticals employs 25 workers across the globe.
What is Newron Pharmaceuticals' official website?
The official website for Newron Pharmaceuticals is www.newron.com .
About Newron Pharmaceuticals
Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide.
Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Newron Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Newron Pharmaceuticals stock.
Newron Announces Half-Year 2021 Results
MILAN, October 18, 2021--Newron Pharmaceuticals S.p.A. has received Tranche 5 under its agreement with the European Investment Bank, consisting of EUR 7.5 million.
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
MILAN, September 16, 2021--Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) today announces its operational and financial results for the half-year ended June 30, 2021.
What is Nephros 2021?
MILAN, September 06, 2021--Newron receives fourth tranche of EUR 7.5 million from Financing Agreement with European Investment Bank for the Company’s development programs.
What is the net revenue of Nephros in 2021?
(Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that Andy Astor, Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest LLC and Maxim Group LLC. The conference will take place on March 17th and 18th from 9:00 am-5:00 pm EST, featuring roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats with live Q&A, and presentations from hundreds of issuers both domestically and internationally. During this virtual conference, Nephros will provide an overview of how they are advancing water safety through pathogen detection and water purification. The conference will feature roundtable discussions, issuer presentations, fireside chats, and live Q&A with company CEOs moderated by Maxim Research Analysts. To learn more about attending, sign up for M-Vest HERE. About Nephros Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees are dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management. For more information about Nephros, please visit www.nephros.com. Investor Relations Contact: Kirin Smith, President PCG Advisory, Inc. (646) 823-8656 [email protected] www.pcgadvisory.com Company Contact: Andy Astor, President and CEO Nephros, Inc. (201) 345-0824 [email protected] www.nephros.com
What is the replay code for Nephros?
Anticipates Net Revenue of $2.7 Million; Highest First Quarter in Company History SOUTH ORANGE, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the first quarter of 2021. Revenue for the quarter ended March 31, 2021 is expected to be $2.7 million, representing growth of 17% over the prior period, and 8% over the same period in 2020. “Despite the pandemic, Nephros accomplished a milestone, recording the highest ever, first-quarter revenue, and the third-highest quarterly revenue in our history. These results, represented by strength in all of our filtration markets – Healthcare, Dialysis, and Commercial – reflect the growth of our underlying business and steady, long-term focus on taking care of our strategic partners and customers,” said Andy Astor, Chief Executive Officer of Nephros. “As more of the country is vaccinated over the coming weeks and months, we anticipate increasingly open markets and a return to pre-pandemic growth rates.” Nephros ended the first quarter with approximately $8.1 million in cash on a consolidated basis. Nephros will announce its first-quarter results on Thursday, May 6, 2021 and will host a conference call that same day at 4:30 PM ET. About Nephros Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees is dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management. For more information about Nephros, please visit www.nephros.com. Forward-Looking Statements This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’s expected revenue for the quarter ended March 31, 2021, expected future growth and the timing of such growth and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including the impact of the ongoing COVID-19 pandemic, uncertainty in clinical outcomes, potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros’s reports filed with the U.S. Securities and Exchange Commission. Nephros does not undertake any responsibility to update the forward-looking statements in this release. Investor Relations Contacts: Kirin Smith, PresidentPCG Advisory, Inc. (646) [email protected] Andy Astor, CEONephros, [email protected] (201) 345-0824
When is Nephros earnings call 2021?
A replay of the call can be accessed until May 13, 2021 at 1-877-344-7529 or 1-412-317-0088 for international callers and entering replay access code: 10153586. An audio archive of the call will be available shortly after the call on the Nephros investor relations page at https://investors.nephros.com/events/.
When is Access to Giving 2021?
(NASDAQ:NEPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.
What is Nephron Pharmaceuticals?
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.
Where is Nephron located?
Nephron Pharmaceuticals Corporation develops and manufacture s safe, affordable inhalation solution and suspension products that help patients with respiratory ailments , such as asthma, emphysema, and chronic obstructive pulmonary disease.
What is the name of the company that makes racemic epinephrine?
Nephron is rooted in the Midlands of South Carolina, both professionally and personally, and we feel passionate about the success of this region. We take pride in knowing that we are impacting lives and making a positive difference in the community.
About Nephros
Nephron is a leader in manufacturing individually wrapped and bar-coded inhalation therapies, and the only manufacturer of Racemic Epinephrine, 2.25%, 0.5mL. Product Information.
Nephros (NASDAQ:NEPH) Frequently Asked Questions
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines.
What is Nephron 503B?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nephros stock. View analyst ratings for Nephros or view top-rated stocks.
Who makes racemic epinephrine?
The Nephron 503B Outsourcing Facility is equipped to manufacture products that are in short supply under Current Good Manufacturing Practice (cGMP) conditions. In an effort to alleviate the ongoing drug shortages in the US drug supply chain, Nephron has responded with 24-7 production of shortage products packaged in prefilled syringes and sterile small-volume parenteral solutions (SVPs). "We will do everything in our power to prevent the delay of necessary patient treatments, and continue to develop shortage list products, with a focus on quality and sterile manufacturing," said Lou Kennedy, CEO.
How many ounces is a pocket nebulizer?
Nephron Pharmaceuticals Corporation is a leading manufacturer of generic respiratory and 503B outsourcing medications. We produce affordable, high-quality inhalation solutions and suspension products that treat respiratory conditions, and we are the only manufacturer of Racemic Epinephrine, 2.25%, 0.5mL.